Actual Medicinal Product (AMP) Mirtazapine 30mg tablets (Genesis Pharmaceuticals Ltd)
Stability Information
(Some stability information inherited from generic)
- Stability
-
Lack of data and/or stability concerns exist. MCA use may be acceptable but is likely to be off-label and require mitigation measures. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or up to 8 weeks if the MCA is airtight (sealed). Consider the risk of potency loss or dose variability and monitor for changes in efficacy or adverse effects after MCA initiation.
- Notes
-
Protect from moisture. Manufacturer recommends storing in original container. No stability data in MCAs available Anecdotal reports of use in MCAs for up to 7 days (low quality evidence)
- Provenance
-
This recommendation is based on the products mirtazapine 30mg film-coated tablets (Accord Healthcare Limited) and mirtazapine 30mg film-coated tablets (Amarox Limited).
- Generic
- Mirtazapine
- Formulation
- Mirtazapine 30mg tablets
-
Mirtazapine
-
Mirtazapine 30mg tablets
-
Mirtazapine 30mg tablets (Genesis Pharmaceuticals Ltd)
-
-
Mirtazapine 2mg capsules
Mirtazapine 15mg orodispersible tablets